Immunex Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Seattle WA United States (1981)
Status: Acquired by Amgen (2002)

Organization Overview

First Clinical Trial
1997
NCT00357903
First Marketed Drug
1981
thiotepa
First NDA Approval
1998
etanercept (enbrel)
Last Known Activity
2009

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

IMMUNEX | Immunex/Berlex | Immunex Corporation

Indications

Approved Indications


 

Arthritis, Juvenile

Arthritis, Psoriatic

Arthritis, Rheumatoid

Psoriasis

Spondylitis, Ankylosing

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Arthritis (Phase 4)

Arthritis, Juvenile (Phase 3)

Arthritis, Psoriatic (Phase 3)

Arthritis, Rheumatoid (Phase 4)

Asthma (Phase 2)

Dermatomyositis (Phase 3)

Leukemia (Phase 2)

Neoplasms (Phase 1)

Osteosarcoma (Phase 2)

Pancreatic Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Psoriasis (Phase 3)

Spondylitis (Phase 3)

Spondylitis, Ankylosing (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 20
  • # of Trial APIs: 15